Advertisement

Topics

Triplet Combo Active in Lenalidomide/Refractory Multiple Myeloma

06:44 EDT 20 Jun 2017 | Cancer Networks

Combining bendamustine, pomalidomide, and dexamethasone achieved a promising overall response rate in patients with heavily pretreated lenalidomide refractory multiple myeloma, according to the results of a phase I/II trial.

Original Article: Triplet Combo Active in Lenalidomide/Refractory Multiple Myeloma

NEXT ARTICLE

More From BioPortfolio on "Triplet Combo Active in Lenalidomide/Refractory Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...